shutterstock_1155148969_atmosphere1
Atmosphere1 / Shutterstock.com
28 October 2021Big PharmaAlex Baldwin

MPP signs first COVID-19 licensing deal over MSD’s molnupiravir

UN-backed public health organisation  The Medicine Patent Pool (MPP) has entered into a licence agreement with  Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

More on this story

Big Pharma
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.

More on this story

Big Pharma
1 June 2021   President Xi Jingping has announced his support for waiving IP rights for COVID-19 vaccines.
Big Pharma
29 July 2021   In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines.
Generics
29 March 2022   Merck Sharp & Dohme and Pfizer have filed three complaints with the Delaware district court to attempt to shut down proposed generics of Steglatro—a diabetes treatment that Pfizer licences to MSD.